Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending August 2012. The report details a specific share repurchase transaction executed on August 3, 2012, in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 600,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,499.5 pence per share; lowest price paid was 1,486.5 pence per share.
- Treasury Holdings (Settled): 483,707,927 shares (8.84% of total issued share capital).
- Treasury Holdings (Including Unsettled): 486,107,927 shares (9.75% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,986,239,097 shares.
Material Changes
The filing reports an increase in the Company's treasury share holdings following the purchase of 600,000 shares. Consequently, the percentage of total voting rights held in Treasury increased to 9.75% when including unsettled shares. No other material changes to financial performance or operations are disclosed in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure regarding share buybacks and voting rights calculations under the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (4,986,239,097) for calculating disclosure thresholds under FSA rules.
- Confirm the current percentage of voting rights held in Treasury (9.75% including unsettled shares).
- Review the price range paid for the repurchased shares (1,486.5 to 1,499.5 pence) against market prices on August 3, 2012.
- Note that this filing does not contain operational or financial performance data; refer to Form 20-F for comprehensive financial statements.